Literature DB >> 19069697

How to treat diversion colitis?--Current state of medical knowledge, own research and experience.

M Szczepkowski1, A Kobus, K Borycka.   

Abstract

The aim of this study was to present current knowledge about a nospecific inflammation of mucosa within segments of colon excluded from normal bowel passage called as a "diversion colitis" (DC) and to try to determine the role of factors which might modify the clinical course of DC. We also unswered the question; how to treat DC: conservatively or surgically? Our own experience with DC concerns 145 patents (which is most numerous and well exactly examined series presented in literature). In the group of patients studied, clinical signs of DC were present in over 70% of patients (early signs were low abdominal pain and tenesmus, while anal oozing appeared later). Predominating endoscopic features of DC in the group of patients studied were: a. blurring of vascular pattern (in app. 90% of patients); b. contact bleeding (in app. 80% of patients); c. mucosal oedema (in app. 60% of patients). Results of own observations and literature data indicate, that morphologic alterations in the segment of bowel excluded from normal passage are probably vasogenic consisting in atrophy and inflammation of the allergic type (this would confirm the theory about vascular etiology of DC). In our material, we have not noticed any trend toward hyperproliferation or dysplasia in the excluded segment of colon, supporting the thesis that these disturbances are largely reversible. Clinical pathology of DC does not depend on age, sex, cause and type of surgical procedure performed, mode of surgery or concomitant diseases. Authors suggested an alternative algorithm of diagnostic work-up in patients suspected of DC, and proposed that patients with a segment of bowel excluded from normal passage be subdivided into three groups: 1. Patients with no clinical, endoscopic nor morphologic signs of DC. 2. Patients with moderate signs of DC. 3. Patients with severe signs of DC. Patients in the group 1 should remain under continuous specialised supervision, because they are at risk of developing DC, while patients in the groups 2 and 3 should undergo surgical restoration of bowel continuity. This applies particularly to group 3, where indications for surgery do not stem from risk of hyperproliferation, dysplasia or malignant transformation, but from that of a massive inflammation, which may constitute a danger for patientis health and even life. Authors also underline that DC can be treated conservatively but the best and most successful and remained method of treatment of DC is the operation of decolostomy, which means restoration continuity of digestive tract.

Entities:  

Mesh:

Year:  2008        PMID: 19069697     DOI: 10.2298/aci0803077s

Source DB:  PubMed          Journal:  Acta Chir Iugosl        ISSN: 0354-950X


  9 in total

1.  A case of fulminant diversion pan-colitis presenting 19 years after colonic diversion for neuronal intestinal dysplasia.

Authors:  Deya Nawrani; Philip Turton; Dermot Burke
Journal:  BMJ Case Rep       Date:  2009-12-30

2.  Enemas with N-acetylcysteine can reduce the level of oxidative damage in cells of the colonic mucosa diverted from the faecal stream.

Authors:  Carlos Augusto Real Martinez; Marcos Gonçalves de Almeida; Camila Moraes Gonçalves da Silva; Marcelo Lima Ribeiro; Fernando Lorenzetti da Cunha; Murilo Rocha Rodrigues; Daniela Tiemi Sato; José Aires Pereira
Journal:  Dig Dis Sci       Date:  2013-07-05       Impact factor: 3.199

3.  Diversion colitis 25 years later: the phenomenon of the disease.

Authors:  Marek Szczepkowski; Tomasz Banasiewicz; Adam Kobus
Journal:  Int J Colorectal Dis       Date:  2017-03-29       Impact factor: 2.571

4.  Effects of anti-TNF-α in experimental diversion colitis.

Authors:  Ronaldo Parisi Buanaim; José Aires Pereira; Fabio Guilherme Campos; Paulo Gustavo Kotze; Eduardo Felipe Kim Goto; Roberta Laís Silva Mendonça; Danilo Toshio Kanno; Carlos Augusto Real Martinez
Journal:  Acta Cir Bras       Date:  2019-12-13       Impact factor: 1.388

5.  Evaluation of intestinal microbiota, short-chain fatty acids, and immunoglobulin a in diversion colitis.

Authors:  Kentaro Tominaga; Atsunori Tsuchiya; Takeshi Mizusawa; Asami Matsumoto; Ayaka Minemura; Kentaro Oka; Motomichi Takahashi; Tomoaki Yosida; Yuzo Kawata; Kazuya Takahashi; Hiroki Sato; Satoshi Ikarashi; Kazunao Hayashi; Ken-Ichi Mizuno; Yosuke Tajima; Masato Nakano; Yoshifumi Shimada; Hitoshi Kameyama; Junji Yokoyama; Toshifumi Wakai; Shuji Terai
Journal:  Biochem Biophys Rep       Date:  2020-12-30

6.  An elemental diet is effective in the management of diversion colitis.

Authors:  Andrew Lane; Nicholas Dalkie; Lisa Henderson; James Irwin; Kamran Rostami
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

7.  Utility of autologous fecal microbiota transplantation and elucidation of microbiota in diversion colitis.

Authors:  Kentaro Tominaga; Atsunori Tsuchiya; Takeshi Mizusawa; Asami Matsumoto; Ayaka Minemura; Kentaro Oka; Motomichi Takahashi; Tomoaki Yoshida; Yuichi Kojima; Kohei Ogawa; Yuzo Kawata; Nao Nakajima; Naruhiro Kimura; Hiroyuki Abe; Toru Setsu; Kazuya Takahashi; Hiroki Sato; Satoshi Ikarashi; Kazunao Hayashi; Ken-Ichi Mizuno; Junji Yokoyama; Yosuke Tajima; Masato Nakano; Yoshifumi Shimada; Hitoshi Kameyama; Toshifumi Wakai; Shuji Terai
Journal:  DEN open       Date:  2021-10-31

8.  Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review.

Authors:  Arianna Dal Buono; Michele Carvello; David B Sachar; Antonino Spinelli; Silvio Danese; Giulia Roda
Journal:  United European Gastroenterol J       Date:  2021-11-29       Impact factor: 4.623

9.  Long-term outcome of indwelling colon observed seven years after radical resection for rectosigmoid cancer: A case report.

Authors:  Zi-Xuan Zhuang; Ming-Tian Wei; Xu-Yang Yang; Yang Zhang; Wen Zhuang; Zi-Qiang Wang
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.